First Quadrant L P CA lowered its stake in Pfizer, Inc. (NYSE:PFE) by 3.4% during the second quarter, Holdings Channel reports. The institutional investor owned 205,674 shares of the biopharmaceutical company’s stock after selling 7,349 shares during the period. First Quadrant L P CA’s holdings in Pfizer were worth $6,909,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the company. Silvercrest Asset Management Group LLC increased its stake in Pfizer by 5.2% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 2,791,070 shares of the biopharmaceutical company’s stock valued at $90,654,000 after buying an additional 138,383 shares in the last quarter. Fiera Capital Corp raised its position in Pfizer by 3.4% in the fourth quarter. Fiera Capital Corp now owns 104,800 shares of the biopharmaceutical company’s stock valued at $3,404,000 after buying an additional 3,432 shares during the last quarter. Levin Capital Strategies L.P. raised its position in Pfizer by 6.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 8,312,581 shares of the biopharmaceutical company’s stock valued at $269,993,000 after buying an additional 474,404 shares during the last quarter. Intellectus Partners LLC purchased a new position in Pfizer during the fourth quarter valued at about $1,296,000. Finally, Moloney Securities Asset Management LLC purchased a new position in Pfizer during the fourth quarter valued at about $809,000. Institutional investors and hedge funds own 70.10% of the company’s stock.

Shares of Pfizer, Inc. (NYSE:PFE) traded up 0.45% during mid-day trading on Wednesday, reaching $33.43. 5,660,071 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $33.43 and a 200 day moving average of $33.25. The firm has a market capitalization of $199.51 billion, a P/E ratio of 24.46 and a beta of 1.00. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.38.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.11% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the company earned $0.64 earnings per share. The company’s revenue was down 1.9% on a year-over-year basis. On average, analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. Pfizer’s payout ratio is presently 94.12%.

WARNING: “First Quadrant L P CA Sells 7,349 Shares of Pfizer, Inc. (PFE)” was originally published by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/09/first-quadrant-l-p-ca-sells-7349-shares-of-pfizer-inc-pfe.html.

Several research analysts have issued reports on PFE shares. Jefferies Group LLC restated a “neutral” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a report on Thursday, April 13th. Sanford C. Bernstein restated a “buy” rating and set a $35.00 price target on shares of Pfizer in a report on Monday, April 24th. BMO Capital Markets restated a “hold” rating and set a $33.00 price target on shares of Pfizer in a report on Thursday, April 27th. Barclays PLC restated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Wednesday, May 3rd. Finally, Citigroup Inc. lowered shares of Pfizer from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $38.00 to $31.00 in a report on Tuesday, May 16th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average target price of $37.77.

In other news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.